Dendrimers: A Themed Issue in Honor of Professor Donald A. Tomalia on the Occasion of His 85th Birthday for His Outstanding Achievements in Advancing the Field of Dendrimers
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 25351
Special Issue Editors
Interests: dendrimers: synthesis and applications; antimicrobial peptides; crystallochemistry; MOF-materials
Special Issues, Collections and Topics in MDPI journals
Interests: dendrimer chemistry; organic and organophosphorus chemistry; macromolecules for catalysis; nanomedicine and materials
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
“Pharmaceutics” is highly pleased to host a themed issue honoring Dr. Donald A. Tomalia for his outstanding achievements in advancing the field of dendrimers on the occasion of his 85th birthday.
Donald A. Tomalia was born in Owosso, Michigan, where he earned his bachelor’s degree in chemistry at the University of Michigan. Soon after graduation, he went to work at Dow. This company supported his doctoral studies in physical organic chemistry at Michigan State University. The initial studies of D. Tomalia concerned cationic polymerization, which were recognized by international industrial awards for creative research in 1978 and 1986. As Dow permitted scientists to explore their own pet projects on Friday afternoons, he proposed building polymers with an ordered, predictable branching structure. His colleagues greeted him with skepticism, but he persisted, and he and some colleagues produced polymers with a central core and tendrils that branched outward, one from another, in a precise, predictable manner. D. Tomalia called them dendrimers in 1985, after dendros, the Greek word for trees and meros for parts. He received another industrial award for creative research in 1991 for such discovery. He played a key role in establishing the place of dendrimers in polymer chemistry, and provided continued inspiration to many in expanding the scope and potential of these well-defined molecular architectures. D. Tomalia holds more than 100 dendrimer-related U.S. patents. He co-founded Dendritech, a dendrimer production company in Midland, Michigan, in 1992, he founded Dendritic NanoTechnologies in Mount Pleasant, Michigan, in a joint venture with StarPharma in Melbourne, Australia, in 2002, a nanotechnology company called NanoSynthons LLC in 2010, and he is CEO and director of the National Dendrimer and Nanotechnology Center located at the NanoSynthons site in Mount Pleasant.
Tomalia was inducted in 2011 into the Thomas Reuters Hall of Citation Laureates in Chemistry, a listing of the 40 most highly cited international scientists in the field of chemistry. He has received many awards for discovering dendritic polymers, including the Leonardo da Vinci award (1996) and Society of Polymer Science Japan award (2003). He worked at Michigan Molecular Institute from 1990-1999 in the capacity as Professor and Director. Then, he served as Adjunct Professor in the Department of Chemistry at the University of Pennsylvania. He co-authored more than 270 articles and several books on dendrimers.
Pharmaceutics invites scientists to submit original contributions to “Dendrimers: A Themed Issue in Honor of Professor Donald A. Tomalia on the Occasion of his 85th Birthday”, and join us in collectively congratulating him for his outstanding accomplishments.
Prof. Dr. Zofia Urbanczyk-Lipkowska
Prof. Dr. Anne-Marie Caminade
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dendrimers
- synthesis
- theranostic
- cancer
- biosensors
- dendrons
- disease treatments
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.